Display options
Cite
Curtis SA, Betancourt J, Kottapalli N, et al. Voxelotor use in adults with sickle cell disease in a real-world setting. Am J Hematol. 2021;doi: 10.1002/ajh.26453.
Curtis, S. A., Betancourt, J., Kottapalli, N., Campbell, S., & Minniti, C. (2021). Voxelotor use in adults with sickle cell disease in a real-world setting. American journal of hematology, . https://doi.org/10.1002/ajh.26453
Curtis, Susanna A, et al. "Voxelotor use in adults with sickle cell disease in a real-world setting." American journal of hematology vol. (2021). doi: https://doi.org/10.1002/ajh.26453
Curtis SA, Betancourt J, Kottapalli N, Campbell S, Minniti C. Voxelotor use in adults with sickle cell disease in a real-world setting. Am J Hematol. 2021 Dec 30; doi: 10.1002/ajh.26453. Epub 2021 Dec 30. PMID: 34967959.
Copy Download .nbib Format: NLM
Share it on

Am J Hematol. 2021 Dec 30; doi: 10.1002/ajh.26453. Epub 2021 Dec 30.

Voxelotor use in adults with sickle cell disease in a real-world setting.

American journal of hematology

Susanna A Curtis, Jaime Betancourt, Niharika Kottapalli, Sean Campbell, Caterina Minniti

Affiliations

  1. Division of Hematology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.
  2. Department of Internal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.
  3. Department of Pathology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.

PMID: 34967959 DOI: 10.1002/ajh.26453

[No abstract available.]

References

  1. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509-519. - PubMed
  2. Rutherford-Parker NJ, Campbell ST, Colby JM, Shajani-Yi Z. Voxelotor treatment interferes with quantitative and qualitative hemoglobin variant analysis in multiple sickle cell disease genotypes. Am J Clin Pathol. 2020;154:627-634. - PubMed
  3. Tsitsikas DA, Kamal M, Braimoh A, Benson S, Abukar J. Hb S (HBB: c.20A>T) characteristics by high performance liquid chromatography in patients with sickle cell disease receiving the novel agent voxelotor. Hemoglobin. 2021;24:1-3. - PubMed
  4. Rutherford NJ, Thoren KL, Shajani-Yi Z, Colby JM. Voxelotor (GBT440) produces interference in measurements of hemoglobin S. Clin Chim Acta. 2018;482:57-59. - PubMed
  5. Howard J, Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133:1865-1875. - PubMed

Publication Types

Grant support